Merus (NASDAQ:MRUS) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Merus (NASDAQ:MRUS) have received an average recommendation of “Buy” from the sixteen brokerages that are currently covering the stock, MarketBeat reports. Fourteen analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $85.31.

Several brokerages recently issued reports on MRUS. Wells Fargo & Company began coverage on Merus in a research note on Friday, February 7th. They set an “overweight” rating and a $91.00 price target on the stock. Guggenheim reaffirmed a “buy” rating on shares of Merus in a report on Wednesday, February 12th. Piper Sandler started coverage on Merus in a report on Thursday, February 13th. They set an “overweight” rating and a $84.00 price objective on the stock. Needham & Company LLC decreased their price objective on Merus from $85.00 to $83.00 and set a “buy” rating on the stock in a report on Friday, February 28th. Finally, Citigroup lifted their price objective on Merus from $89.00 to $97.00 and gave the company a “buy” rating in a report on Monday, December 9th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Polar Asset Management Partners Inc. bought a new position in Merus in the 4th quarter worth approximately $1,318,000. GF Fund Management CO. LTD. bought a new position in Merus in the 4th quarter worth approximately $60,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Merus by 17.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 98,744 shares of the biotechnology company’s stock worth $4,152,000 after purchasing an additional 14,544 shares during the last quarter. Woodline Partners LP raised its position in Merus by 0.3% in the 4th quarter. Woodline Partners LP now owns 1,188,518 shares of the biotechnology company’s stock worth $49,977,000 after purchasing an additional 3,593 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new position in Merus in the 4th quarter worth approximately $817,000. Institutional investors own 96.14% of the company’s stock.

Merus Stock Up 0.3 %

Shares of MRUS opened at $47.22 on Thursday. Merus has a 12-month low of $37.77 and a 12-month high of $61.61. The firm has a market capitalization of $3.26 billion, a price-to-earnings ratio of -11.95 and a beta of 1.15. The stock’s 50-day moving average price is $42.99 and its 200 day moving average price is $46.28.

Merus (NASDAQ:MRUS) last issued its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.48. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The firm had revenue of $9.14 million for the quarter, compared to analyst estimates of $10.57 million. Equities research analysts expect that Merus will post -3.85 EPS for the current year.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.